Vilin Bio Med IPO Listing: Disappointment for Investor
Vilin Bio Med IPO Listing
Vilin Bio Med, a prominent player in the pharmaceutical sector, went public with an initial public offering (IPO) and listed its shares on the SME platform of the National Stock Exchange (NSE) today.
The IPO garnered significant interest, with the subscription rate reaching over two and a half times the number of shares available.
The shares were initially issued to IPO investors at a price of Rs 30 per share, and the stock debuted on the market at the same price, resulting in no immediate listing gains for the investors.
However, following its listing, the shares of Vilin Bio Med faced selling pressure, leading to a decline in their value.
At the end of the first day of trading, the shares closed at Rs 28.50 per share. This closing price indicates that the IPO investors experienced a loss of Rs 1.5 per share, as the shares declined in value from their initial price.
It’s worth noting that the stock market is subject to various factors that can influence share prices, including market sentiment, investor demand, company performance, and overall economic conditions.
The decline in Vilin Bio Med’s share price on the first day of trading suggests that there was selling pressure, indicating that some investors chose to sell their shares, possibly due to factors such as profit-taking or concerns about the company’s prospects.
How Was the Response to Vilin Bio Med IPO?
The IPO of Vilin Bio Med received a positive response from investors. The company issued 40 lakh new equity shares with a face value of Rs 10 each, as part of its Rs 12 crore IPO.
The overall subscription rate for the IPO was 2.80 times, indicating that the total number of shares applied for exceeded the number of shares available by 2.80 times.
The reserved portion of the IPO, specifically allocated for retail investors, received even higher demand. The retail portion was subscribed 4.31 times, indicating that retail investors applied for 4.31 times the number of shares reserved for them.
The strong subscription rates in both the overall and retail categories indicate that there was significant investor interest in Vilin Bio Med’s IPO. The oversubscription suggests that investors saw value in investing in the company and were willing to participate in the offering.
By issuing new shares and raising funds through the IPO, Vilin Bio Med aims to utilize the capital for various purposes.
The company intends to allocate the raised funds to meet its working capital requirements, which can include financing day-to-day operations, managing inventory, and supporting business growth.
Additionally, the funds will be used for general corporate purposes, which may involve strategic investments, research and development, marketing initiatives, and other activities to strengthen the company’s overall operations.
Overall, the response to Vilin Bio Med’s IPO indicates positive investor sentiment and confidence in the company’s prospects, as evidenced by the oversubscription in both the overall and retail categories.
Details about Vilin Bio Med Company
Vilin Bio Med is a pharmaceutical company that was established in 2005. The company primarily focuses on the manufacturing of pharmaceutical products and operates by selling its products in bulk to marketers and traders.
Vilin Bio Med’s research and development center, as well as its manufacturing facility, are located in Roorkee, Uttarakhand.
In terms of financial performance, the company experienced a notable improvement in the last financial year. From April to December 2022, Vilin Bio Med achieved a net profit of Rs 1.28 crore.
This represents a substantial increase compared to the net profit of Rs 3.35 lakh recorded for the entire financial year 2022 prior to that period.
However, Vilin Bio Med witnessed a slowdown in terms of revenue growth. In the financial year 2022, the company generated a revenue of Rs 11.22 crore. However, during the nine-month period from April to December 2022, the company’s revenue decreased to Rs 9.03 crore.
It’s important to note that fluctuations in revenue and profitability can occur in the pharmaceutical industry due to various factors such as product demand, competition, regulatory changes, and market conditions.
The increase in net profit during the April-December 2022 period indicates positive financial performance for Vilin Bio Med, while the decline in revenue suggests the need for further analysis and understanding of the underlying factors influencing the company’s sales.
Investors and stakeholders should consider conducting a comprehensive assessment of Vilin Bio Med’s financial statements, industry trends, competitive landscape, and growth prospects to make informed investment decisions.
